JPRN-UMIN000006927已完成2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patients - Effect of extended dose interval on the immun induction - - Personalized peptide vaccine trial for cancer patients - Effect of extended dose interval on the immun induction
Kurume University Cancer Vaccine Center0 个研究点目标入组 60 人开始时间: 2011年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2) Patients with the past history of severe allergic reactions. 3) Pregnant, nursing, or who wants pregnancy. Patients with no acceptance of use effective contraception during and for at least 70 days after study participation. 4) Patients who are judged inappropriate for the clinical trial by doctors.
研究者
相似试验
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patientsmalignant tumorJPRN-UMIN000001482Kurume University Cancer Vaccine Center150
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for patients with maligant tumors (gastrointestinal cancers, hepato-biliary-pancreatic cancers, thoracic malignant tumors, non-epithelial malignant tumors, genitourinary cancers, gynecological cancers, breast cancers, and rare cancers) - Effect of extended interval dosing on immune responsesmalignant tumorJPRN-UMIN000011230Kurume University CanCER Vaccine Center800
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for patients with various types of cancers - Effect of sequencial change of vaccine antigensmalignant tumorJPRN-UMIN000010068Kurume University Cancer Vaccine Center100
已完成
2 期
Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic urotherial cancer previously treated with M-VAC chemotherapyrotherial cancerJPRN-UMIN000001061Kurume University School of medicine, Department of Immunology20
已完成
2 期
Phase II clinical trial of personalized peptide vaccination for standard therapy failure patients with malignant glioma (glioblastoma)malignant glioma (glioblastoma)JPRN-UMIN000001243Department of Immunology, Kurume University School of medicine40